the mechanism of action of durvalumab in the treatment of urothelial bladder cancer
Published 7 years ago • 1.3K plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
3:19
fda approval of durvalumab for advanced bladder cancer
-
0:53
dr. siefker-radtke on fda approval of durvalumab in bladder cancer
-
1:10
dr. powles discusses the future of durvalumab in bladder cancer
-
2:55
highlights of durvalumab for advanced bladder cancer
-
2:03
durvalumab fda approval for bladder cancer
-
4:21
durvalumab for treatment of advanced bladder cancer
-
2:36
exploring durvalumab with radiation therapy in patients with urothelial carcinoma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:43
dr. sonpavde discusses a study of fixed-dose durvalumab and tremelimumab in urothelial carcinoma
-
1:05
dr. sonpavde on the role of durvalumab in platinum-refractory bladder cancer
-
1:37
results for durvalumab in the second-line treatment of nsclc
-
4:38
danube trial: durvalumab alone or with tremelimumab for metastatic bladder cancer
-
1:23
how effective is pembrolizumab in cisplatin-ineligible bladder cancer? results from keynote-052
-
1:08
dr. rafii on durvaluamb in patients with urothelial bladder cancer
-
0:52
dr. black discusses the impact of durvalumab in bladder cancer
-
1:08
future treatment approaches for patients with bladder cancer
-
1:49
fda approval of durvalumab for bladder cancer
-
1:00
trial of durvalumab for bladder cancer
-
1:18
a study of chemotherapy with durvalumab and tremelimumab in nsclc